Analyst Thinks Johnson & Johnson Could Hit a $280 Target
A major analyst raises the price target on Johnson & Johnson to $280, arguing growing oncology sales and a planned sp...
This article explains practical timing for rebalancing index funds in retirement, helping you maintain targets and smooth withdrawals.
15,959 articlesA major analyst raises the price target on Johnson & Johnson to $280, arguing growing oncology sales and a planned sp...
WM Technology MAPS is weighing a pivotal year. This guide breaks down the Q4 2025 earnings, what technology (maps) 20...
Two early leaders in the electric air taxi race collide with a policy signal that could tilt the field. This analysis...
NovaBridge Crypto cuts 12% of its workforce to accelerate its AI strategy, signaling a wider shift toward AI-driven e...
Finding value in semiconductors is tough, but a disciplined approach can spot opportunities amid rapid tech change. L...
XRP continues to slide in March 2026 despite regulatory wins and Brazil expansion, with traders weighing macro risks,...
Three weeks into iran, the conflict has pushed energy prices higher and tightened budgets for families. Here’s what h...
Markets swing between fear and opportunity. This guide shows how to identify a growth stock dynamo before a breakout,...
Circle has delivered a dramatic swing in 2024. This article breaks down the main reason it could keep climbing, the r...
A single stock in the AI conversation may be quietly delivering outsized, long-term gains. Learn why this Magnificent...
Figuring out what considered good stock dividends means looking beyond yield. This article breaks down the metrics th...
Tether converts a historic $13 billion profit into a bold health-tech investment, backing Eight Sleep at a $1.5 billi...